سوق ساركوما العظام العالمي - اتجاهات الصناعة والتوقعات حتى عام 2030

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL OSTEOSARCOMA MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE GLOBAL XX SIZE

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 GLOBAL OSTEOSARCOMA MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES MODEL

5 INDUSTRY INSIGHTS

5.1 PATENT ANALYSIS

5.1.1 PATENT LANDSCAPE

5.1.2 USPTO NUMBER

5.1.3 PATENT EXPIRY

5.1.4 EPIO NUMBER

5.1.5 PATENT STRENGTH AND QUALITY

5.1.6 PATENT CLAIMS

5.1.7 PATENT CITATIONS

5.1.8 PATENT LITIGATION AND LICENSING

5.1.9 FILE OF PATENT

5.1.10 PATENT RECEIVED CONTRIES

5.1.11 TECHNOLOGY BACKGROUND

5.2 DRUG TREATMENT RATE BY MATURED MARKETS

5.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES

5.4 PATIENT FLOW DIAGRAM

5.5 KEY PRICING STRATEGIES

5.6 KEY PATIENT ENROLLMENT STRATEGIES

5.7 INTERVIEWS WITH SPECIALIST

5.8 OTHER KOL SNAPSHOTS

6 EPIDEMIOLOGY

6.1 INCIDENCE OF ALL BY GENDER

6.2 TREATMENT RATE

6.3 MORTALITY RATE

6.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL

6.5 PATIENT TREATMENT SUCCESS RATES

7 MERGERS AND ACQUISITION

7.1 LICENSING

7.2 COMMERCIALIZATION AGREEMENTS

8 REGULATORY FRAMEWORK

8.1 REGULATORY APPROVAL PROCESS

8.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL

8.3 REGULATORY APPROVAL PATHWAYS

8.4 LICENSING AND REGISTRATION

8.5 POST-MARKETING SURVEILLANCE

8.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES

9 PIPELINE ANALYSIS

9.1 CLINICAL TRIALS AND PHASE ANALYSIS

9.2 DRUG THERAPY PIPELINE

9.3 PHASE III CANDIDATES

9.4 PHASE II CANDIDATES

9.5 PHASE I CANDIDATES

9.6 OTHERS (PRE-CLINICAL AND RESEARCH)

TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR GLOBAL OSTEOSARCOMA TREATMENT MARKET

Company Name Therapeutic Area

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE

Phase Number of Projects

Preclinical/Research Projects XX

Clinical Development XX

Phase I XX

Phase II XX

Phase III XX

U.S. Filed/Approved But Not Yest Marketed XX

Total XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE

Therapeutic Area Preclinical/ Research Project

XX XX

XX XX

XX XX

XX XX

XX XX

Total Projects XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE

Technology Preclinical/ Research Project

XX XX

XX XX

XX XX

XX XX

XX XX

Total Projects XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR GLOBAL OSTEOSARCOMA TREATMENT MARKET

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

10 MARKETED DRUG ANALYSIS

10.1 DRUG

10.1.1 BRAND NAME

10.1.2 GENERICS NAME

10.2 THERAPEUTIC INDIACTION

10.3 PHARACOLOGICAL CLASS OD THE DRUG

10.4 DRUG PRIMARY INDICATION

10.5 MARKET STATUS

10.6 MEDICATION TYPE

10.7 DRUG DOSAGES FORM

10.8 DOSAGES AVAILABILITY

10.9 PACKAGING TYPE

10.1 DRUG ROUTE OF ADMINISTRATION

10.11 DOSING FREQUENCY

10.12 DRUG INSIGHT

10.13 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.

10.13.1 FORECAST MARKET OUTLOOK

10.13.2 CROSS COMPETITION

10.13.3 THERAPEUTIC PORTFOLIO

10.13.4 CURRENT DEVELOPMENT SCENARIO

11 MARKET ACCESS

11.1 10-YEAR MARKET FORECAST

11.2 CLINICAL TRIAL RECENT UPDATES

11.3 ANNUAL NEW FDA APPROVED DRUGS

11.4 DRUGS MANUFACTURER AND DEALS

11.5 MAJOR DRUG UPTAKE

11.6 CURRENT TREATMENT PRACTICES

11.7 IMPACT OF UPCOMING THERAPY

12 R & D ANALYSIS

12.1 COMPARATIVE ANALYSIS

12.2 DRUG DEVELOPMENTAL LANDSCAPE

12.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES

12.4 THERAPEUTIC ASSESSMENT

12.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS

13 MARKET OVERVIEW

13.1 DRIVERS

13.2 RESTRAINTS

13.3 OPPORTUNITIES

13.4 CHALLENGES

14 GLOBAL OSTEOSARCOMA TREATMENT MARKET, SWOT AND DBMR ANALYSIS

15 GLOBAL OSTEOSARCOMA MARKET, BY TREATMENT & DIAGNOSIS

15.1 OVERVIEW

15.2 TREATMENT

15.2.1 MEDICATION

15.2.1.1. MARKETED DRUGS

15.2.1.1.1. CHEMOTHERAPY

15.2.1.1.1.1 METHOTREXATE

15.2.1.1.1.2 DOXORUBICIN (ADRIAMYCIN)

15.2.1.1.1.3 IFSOSFAMIDE

15.2.1.1.1.4 ETOPOSIDE

15.2.1.1.1.5 GEMCITABINE

15.2.1.1.1.6 OTHERS

15.2.1.1.2. TARGETED THERAPY

15.2.1.1.2.1 KINASE INHIBITOR THERAPY

15.2.1.1.2.1.1. CABOZANTINIB

15.2.1.1.2.1.2. REGORAFENIB

15.2.1.1.2.1.3. OTHERS

15.2.1.1.2.2 MAMMALIAN TARGET OF RAPAMYCIN (MTOR) INHIBITORS

15.2.1.1.2.2.1. EVEROLIMUS

15.2.1.1.2.2.2. OTHERS

15.2.1.1.3. SAMARIUM

15.2.1.1.3.1 LEXIDRONAM

15.2.1.1.3.2 OTHERS

15.2.1.2. EMERGING/PIPELINE DRUGS

15.2.1.2.1. CHEMOTHERAPY

15.2.1.2.1.1 CISPLASTIN

15.2.1.2.1.2 PAMIDRONATE

15.2.1.2.1.3 SURUFATINIB

15.2.1.2.1.4 ENDOSTAR

15.2.1.2.1.5 OTHERS

15.2.1.2.2. TARGETED THERAPY

15.2.1.2.2.1 PAZOPANIB

15.2.1.2.2.2 OTHERS

15.2.1.2.3. IMMUNOTHERAPY

15.2.1.2.3.1 NIVOLUMAB

15.2.1.2.3.2 OTHERS

15.2.1.2.4. KINASE INHIBITORS

15.2.1.2.4.1 ALIQOPA

15.2.1.2.4.2 REGORAFENIB

15.2.1.2.4.3 CABOZANTINIB S-MALATE

15.2.1.2.4.4 OTHERS

15.2.2 RADIATION THERAPY

15.2.2.1. EXTERNAL RADIATION THERAPY

15.2.2.1.1. INTENSITY MODULATED RADIATION THERAPY (IMRT)

15.2.2.1.2. CONFORMAL RADIATION BEAM THERAPY

15.2.2.1.3. STEREOTACTIC RADIOSURGERY

15.2.2.1.4. OTHERS

15.2.2.2. INTERNAL RADIATION THERAPY

15.2.2.2.1. BRACHYTHERAPY

15.2.2.2.2. OTHERS

15.2.3 SURGERY

15.2.3.1. LIMB-SPARING SURGERY

15.2.3.2. AMPUTATION

15.2.3.3. ROTATIONPLASTY

15.2.3.4. WIDE LOCAL EXCISION

15.2.3.5. METASTASECTOMY

15.3 DIAGNOSIS

15.3.1 IMAGING

15.3.1.1. COMPUTED TOMOGRAPHY (CT)

15.3.1.2. MAGNETIC RESONANCE IMAGING (MRI)

15.3.1.3. X-RAY

15.3.1.4. POSITRON EMISSION TOMOGRAPHY (PET)

15.3.1.5. OTHERS

15.3.2 BIOPSIES

15.3.2.1. CORE BIOPSY

15.3.2.2. INCISIONAL BIOPSY

15.3.3 BLOOD TEST

15.3.3.1. COMPLETE BLOOD TEST (CBC)

15.3.3.2. BLOOD CHEMISTRY TESTS

16 GLOBAL OSTEOSARCOMA MARKET, BY TYPE

16.1 OVERVIEW

16.2 CENTRAL TUMOR (MEDULLARY)

16.2.1 CONVENTIONAL CENTRAL OSTEOSARCOMA

16.2.2 TELANGIECTATIC OSTEOSARCOMA

16.2.3 INTRAOSSEOUS WELL-DIFFERENTIATED OSREOSARCOMA

16.2.4 SMALL CELL OSTEOSARCOMA

16.3 SURFACE TUMOR (PERIPHERAL)

16.3.1 PAROSTEAL WELL-DIFFERENTIATED

16.3.2 PERIOSTEAL OSTEOSARCOMA

16.3.3 HIGH-GRADE SURFACE OSTEOSARCOMA

17 GLOBAL OSTEOSARCOMA MARKET, BY STAGES

17.1 OVERVIEW

17.2 LOW-GRAD

17.2.1 PAROSTEAL (JUXTACORTIAL LOW GRADE).

17.2.2 INTRAMEDULLARY OR INTRAOSSEOUS WELL-DIFFERENTIATED (LOW-GRADE CENTRAL)

17.3 HIGH-GRADE

17.3.1 OSTEOBLASTIC.

17.3.2 CHONDROBLASTIC.

17.3.3 FIBROBLASTIC.

17.3.4 SMALL CELL.

17.3.5 TELANGIECTATIC.

17.3.6 HIGH-GRADE SURFACE (JUXTACORTICAL HIGH-GRADE).

17.3.7 PAGETOID.

17.3.8 EXTRASKELETAL.

17.3.9 POST-RADIATION.

17.4 INTERMEDIATE GRADE (JUXTACORTICAL)

18 GLOBAL OSTEOSARCOMA MARKET, BY ROUTE OF ADMINISTRATION

18.1 OVERVIEW

18.2 PARENTERAL

18.3 ORAL

18.4 OTHERS

19 GLOBAL OSTEOSARCOMA MARKET, BY DOSAGE FORM

19.1 OVERVIEW

19.2 ORAL

19.2.1 PILLS

19.2.2 TABLETS

19.2.3 CAPSULES

19.2.4 OTHERS

19.3 INTRAVENOUS

19.4 SUBCUTANOUS

19.5 OTHERS

20 GLOBAL OSTEOSARCOMA MARKET, BY AGE GROUP

20.1 OVERVIEW

20.2 ADULT

20.3 GERIARTIC

20.4 PEDIATRIC

21 GLOBAL OSTEOSARCOMA MARKET, BY END USER

21.1 OVERVIEW

21.2 HOSPITALS & CLINICS

21.3 DIAGNOSTIC CENTERS

21.4 ACADEMIC & RESEARCH INSTITUTES

21.5 OTHERS

22 GLOBAL OSTEOSARCOMA MARKET, BY DISTRIBUTION CHANNEL

22.1 OVERVIEW

22.2 DIRECT TENDER

22.3 RETAIL SALES

22.3.1 HOSPITAL PHARMACIES

22.3.2 ONLINE PHARMACIES

22.3.3 OTHERS

22.4 OTHERS

23 GLOBAL OSTEOSARCOMA TREATMENT MARKET, COMPANY LANDSCAPE

23.1 COMPANY SHARE ANALYSIS: GLOBAL

23.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

23.3 COMPANY SHARE ANALYSIS: EUROPE

23.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

23.5 MERGERS & ACQUISITIONS

23.6 NEW PRODUCT DEVELOPMENT & APPROVALS

23.7 EXPANSIONS

23.8 REGULATORY CHANGES

23.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

24 GLOBAL OSTEOSARCOMA TREATMENT MARKET, BY REGION

GLOBAL OSTEOSARCOMA TREATMENT MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

24.1 NORTH AMERICA

24.1.1 U.S.

24.1.2 CANADA

24.1.3 MEXICO

24.2 EUROPE

24.2.1 GERMANY

24.2.2 U.K.

24.2.3 ITALY

24.2.4 FRANCE

24.2.5 SPAIN

24.2.6 RUSSIA

24.2.7 SWITZERLAND

24.2.8 TURKEY

24.2.9 BELGIUM

24.2.10 NETHERLANDS

24.2.11 DENMARK

24.2.12 SWEDEN

24.2.13 POLAND

24.2.14 NORWAY

24.2.15 FINLAND

24.2.16 REST OF EUROPE

24.3 ASIA-PACIFIC

24.3.1 JAPAN

24.3.2 CHINA

24.3.3 SOUTH KOREA

24.3.4 INDIA

24.3.5 SINGAPORE

24.3.6 THAILAND

24.3.7 INDONESIA

24.3.8 MALAYSIA

24.3.9 PHILIPPINES

24.3.10 AUSTRALIA

24.3.11 NEW ZEALAND

24.3.12 VIETNAM

24.3.13 TAIWAN

24.3.14 REST OF ASIA-PACIFIC

24.4 SOUTH AMERICA

24.4.1 BRAZIL

24.4.2 ARGENTINA

24.4.3 REST OF SOUTH AMERICA

24.5 MIDDLE EAST AND AFRICA

24.5.1 SOUTH AFRICA

24.5.2 EGYPT

24.5.3 BAHRAIN

24.5.4 UNITED ARAB EMIRATES

24.5.5 KUWAIT

24.5.6 OMAN

24.5.7 QATAR

24.5.8 SAUDI ARABIA

24.5.9 REST OF MEA

24.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

25 GLOBAL OSTEOSARCOMA TREATMENT MARKET, COMPANY PROFILE

25.1 CELLECTAR BIOSCIENCES, INC

25.1.1 COMPANY OVERVIEW

25.1.2 REVENUE ANALYSIS

25.1.3 GEOGRAPHIC PRESENCE

25.1.4 PRODUCT PORTFOLIO

25.1.5 RECENT DEVELOPMENTS

25.2 NOVARTIS

25.2.1 COMPANY OVERVIEW

25.2.2 REVENUE ANALYSIS

25.2.3 GEOGRAPHIC PRESENCE

25.2.4 PRODUCT PORTFOLIO

25.2.5 RECENT DEVELOPMENTS

25.3 PFIZER INC.

25.3.1 COMPANY OVERVIEW

25.3.2 REVENUE ANALYSIS

25.3.3 GEOGRAPHIC PRESENCE

25.3.4 PRODUCT PORTFOLIO

25.3.5 RECENT DEVELOPMENTS

25.4 HIKMA PHARMACEUTICAL

25.4.1 COMPANY OVERVIEW

25.4.2 REVENUE ANALYSIS

25.4.3 GEOGRAPHIC PRESENCE

25.4.4 PRODUCT PORTFOLIO

25.4.5 RECENT DEVELOPMENTS

25.5 SPECTRUM PHARMACEUTICAL

25.5.1 COMPANY OVERVIEW

25.5.2 REVENUE ANALYSIS

25.5.3 GEOGRAPHIC PRESENCE

25.5.4 PRODUCT PORTFOLIO

25.5.5 RECENT DEVELOPMENTS

25.6 ASTRAZENECA

25.6.1 COMPANY OVERVIEW

25.6.2 REVENUE ANALYSIS

25.6.3 GEOGRAPHIC PRESENCE

25.6.4 PRODUCT PORTFOLIO

25.6.5 RECENT DEVELOPMENTS

25.7 ZENTALIS PHARMACEUTICALS

25.7.1 COMPANY OVERVIEW

25.7.2 REVENUE ANALYSIS

25.7.3 GEOGRAPHIC PRESENCE

25.7.4 PRODUCT PORTFOLIO

25.7.5 RECENT DEVELOPMENTS

25.8 GSK

25.8.1 COMPANY OVERVIEW

25.8.2 REVENUE ANALYSIS

25.8.3 GEOGRAPHIC PRESENCE

25.8.4 PRODUCT PORTFOLIO

25.8.5 RECENT DEVELOPMENTS

25.9 SAM BIOSCIENCES

25.9.1 COMPANY OVERVIEW

25.9.2 REVENUE ANALYSIS

25.9.3 GEOGRAPHIC PRESENCE

25.9.4 PRODUCT PORTFOLIO

25.9.5 RECENT DEVELOPMENTS

25.1 RADIOPHARM THERANOSTICS

25.10.1 COMPANY OVERVIEW

25.10.2 REVENUE ANALYSIS

25.10.3 GEOGRAPHIC PRESENCE

25.10.4 PRODUCT PORTFOLIO

25.10.5 RECENT DEVELOPMENTS

25.11 ISOFOL MEDICAL AB

25.11.1 COMPANY OVERVIEW

25.11.2 REVENUE ANALYSIS

25.11.3 GEOGRAPHIC PRESENCE

25.11.4 PRODUCT PORTFOLIO

25.11.5 RECENT DEVELOPMENTS

25.12 ADVAXIS, INC

25.12.1 COMPANY OVERVIEW

25.12.2 REVENUE ANALYSIS

25.12.3 GEOGRAPHIC PRESENCE

25.12.4 PRODUCT PORTFOLIO

25.12.5 RECENT DEVELOPMENTS

26 RELATED REPORTS

27 CONCLUSION

28 QUESTIONNAIRE

29 ABOUT DATA BRIDGE MARKET RESEARCH